-transparent.png){kind=logo}
Highly purified human lymphoblastoid interferon derived from virus-stimulated Namalwa cells was administered daily by 6-h i.v. infusion or i.m. injection to 40 patients with a variety of disseminated malignancies refractory to standard therapy. Each patient received escalating doses of 0.1-50 X 10(6) U for up to 5 weeks. Extensive monitoring for changes in various immune functions revealed no sustained elevation in natural killer cell activity, elevated monocyte-mediated antitumor cytostatic activity in approximately 30% of the patients, and depressed lymphoproliferative responses to mitogens and mixed leukocyte culture.
Related Publications
A E Maluish, and
J R Ortaldo, and
S A Sherwin, and
R K Oldham, and
R B Herberman
November 1986,
Hawaii medical journal,
A E Maluish, and
J R Ortaldo, and
S A Sherwin, and
R K Oldham, and
R B Herberman
January 1978,
Acta medica Scandinavica,
A E Maluish, and
J R Ortaldo, and
S A Sherwin, and
R K Oldham, and
R B Herberman
October 1980,
International journal of cancer,
A E Maluish, and
J R Ortaldo, and
S A Sherwin, and
R K Oldham, and
R B Herberman
October 1980,
International journal of cancer,
A E Maluish, and
J R Ortaldo, and
S A Sherwin, and
R K Oldham, and
R B Herberman
February 1984,
Cancer nursing,
A E Maluish, and
J R Ortaldo, and
S A Sherwin, and
R K Oldham, and
R B Herberman
October 1987,
Journal of interferon research,
A E Maluish, and
J R Ortaldo, and
S A Sherwin, and
R K Oldham, and
R B Herberman
September 1986,
Immunobiology,
A E Maluish, and
J R Ortaldo, and
S A Sherwin, and
R K Oldham, and
R B Herberman
January 1991,
Oncology,
A E Maluish, and
J R Ortaldo, and
S A Sherwin, and
R K Oldham, and
R B Herberman
August 2019,
Journal of critical care,
A E Maluish, and
J R Ortaldo, and
S A Sherwin, and
R K Oldham, and
R B Herberman
May 1982,
Journal of the National Cancer Institute,
